The 5-year survival from lung cancer has kept pace with the improvement in 5-year survival from all cancers over the last 40 years. Yet, it remains disappointingly low at ~15%. This improvement in 5-year survival is a result of heightened awareness, better technology for detection, better selection of patients for various therapeutic options, and the selective use of palliative interventions. However, lung cancer mortality remains extraordinarily high, and it is the benchmark by which future generations will judge our success in effectively combating this disease. The Moffitt Cancer Center SPORE in Lung Cancer will 1) elucidate mechanisms of action of crucial molecules in lung carcinogenesis and tumor progression and investigate their impact on therapeutic efficacy and 2) prospectively assess the clinical utility of the molecules for therapeutic and prevention interventions. Our ultimate goal is to change the standard of care for people at risk for and with lung cancer. The SPORE has five translational research projects, three cores, a developmental research program, and a career development program. The projects are: 1) E2Fs Impact on Therapeutic Efficacy (Cress, Chen &Bepler) 2) RRM1 in the Management of Lung Cancer (Bepler, Cress &Simon) 3) Antitumor Mechanisms of Src Inhibitors in Lung Cancer (Haura, Cheng &Pledger) 4) Lung Cancer Chemoprevention with Enzastaurin (Bepler &Alexandrow) 5) p53-Based Vaccine for Small Cell Lung Cancer (Gabrilovich &Antonia) They are support by: A) Tissue Procurement, Pathology, and Bioinformatics Core (Altiok &Fenstermacher) B) Clinical Trials &Biostatistics Core (Simon, Schell &Bepler) C) Administration &Patient Advocacy Core (Bepler, Cress &Quinn). The SPORE also has Developmental Research &Career Development Programs. This SPORE will be firmly integrated into the H. Lee Moffitt Cancer Center and Research Institute, a free-standing, NCI designated Comprehensive Cancer in Tampa, Florida.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA119997-05S1
Application #
8528755
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Lin, Alison J
Project Start
2008-09-15
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$94,360
Indirect Cost
$38,360
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Chen, Lu; Kurtyka, Courtney A; Welsh, Eric A et al. (2016) Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma. Oncotarget :
Huynh, Amanda Shanks; Estrella, Veronica; Stark, Valerie E et al. (2016) Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5. Mol Pharm 13:534-44
Jhuraney, Ankita; Woods, Nicholas T; Wright, Gabriela et al. (2016) PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Mol Cancer Ther 15:1669-81
Schabath, M B; Welsh, E A; Fulp, W J et al. (2016) Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35:3209-16
Chen, Lu; Engel, Brienne E; Welsh, Eric A et al. (2016) A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma. J Thorac Oncol 11:838-49
Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029
Yoshida, Takeshi; Song, Lanxi; Bai, Yun et al. (2016) ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS One 11:e0147344
Huang, Qingling; Schneeberger, Valentina E; Luetteke, Noreen et al. (2016) Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma. Mol Cancer Ther 15:2521-2529
Chen, Zirong; Li, Jian-Liang; Lin, Shuibin et al. (2016) cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest 126:2267-79
Grove, Olya; Berglund, Anders E; Schabath, Matthew B et al. (2015) Quantitative computed tomographic descriptors associate tumor shape complexity and intratumor heterogeneity with prognosis in lung adenocarcinoma. PLoS One 10:e0118261

Showing the most recent 10 out of 83 publications